http://ift.tt/2oMaKGK
The company has received “final approval from the United States Food and Drug Administration (USFDA) to market olmesartan medoxomil tablets in the strengths of 5 mg, 20 mg and 40 mg”, Cadila Healthcare said in a filing to BSE. The drug is an anti-hypertensive and will be produced at the group#39;s formulations manufacturing facility in Ahmedabad, it added.
April 25, 2017 at 02:32PM
from
No comments:
Post a Comment